22 June 2026
22 June 2026
Out of 109 participants, 48 received early treatment, accounting for 44% of the trial population.
The approved indications include combining Sarclisa SC with Pd, or with carfilzomib for relapsed or refractory multiple myeloma.
By incorporating nonclinical testing services, the partnership seeks to standardise testing protocols across organisations.
The trial is studying ateganosine followed by cemiplimab in NSCLC patients resistant to checkpoint inhibitors and chemotherapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
